Switch theme
Sign up to access all valuation multiples
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
1984
34
Last FY Revenue $0.1M
Last FY EBITDA -$131M
$509M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Opthea achieved revenue of $0.1M and an EBITDA of -$131M.
Opthea expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Opthea valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$131M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -159858% | XXX | XXX | XXX |
| EBIT | XXX | -$126M | XXX | XXX | XXX |
| EBIT Margin | XXX | -153885% | XXX | XXX | XXX |
| Net Profit | XXX | -$144M | XXX | XXX | XXX |
| Net Margin | XXX | -176666% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Opthea's stock price is AUD 1 (or $0).
Opthea has current market cap of AUD 739M (or $484M), and EV of AUD 778M (or $509M).
See Opthea trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $509M | $484M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Opthea has market cap of $484M and EV of $509M.
Opthea's trades at 6673.2x EV/Revenue multiple, and -4.7x EV/EBITDA.
Equity research analysts estimate Opthea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Opthea's P/E ratio is not available.
See valuation multiples for Opthea and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $484M | XXX | $484M | XXX | XXX | XXX |
| EV (current) | $509M | XXX | $509M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 6673.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -4.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -4.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOpthea's revenue per employee in the last FY averaged $2K, while opex per employee averaged $3.7M for the same period.
Opthea's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Opthea's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Opthea and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 141439% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 153985% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Opthea acquired XXX companies to date.
Last acquisition by Opthea was XXXXXXXX, XXXXX XXXXX XXXXXX . Opthea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Opthea founded? | Opthea was founded in 1984. |
| Where is Opthea headquartered? | Opthea is headquartered in Australia. |
| How many employees does Opthea have? | As of today, Opthea has 34 employees. |
| Who is the CEO of Opthea? | Opthea's CEO is Dr. Frederic Guerard, Pharm.D.. |
| Is Opthea publicy listed? | Yes, Opthea is a public company listed on ASX. |
| What is the stock symbol of Opthea? | Opthea trades under OPT ticker. |
| When did Opthea go public? | Opthea went public in 1991. |
| Who are competitors of Opthea? | Similar companies to Opthea include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Opthea? | Opthea's current market cap is $484M |
| Is Opthea profitable? | Yes, Opthea is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
